14062-05-6 Usage
General Description
These three chemicals are all derivatives of hydrazine with tosyl groups attached. 1,2-Bis(p-tolylsulfonyl)hydrazine is a dihydrazide compound used in the synthesis of polymeric and organic compounds, while N,Nμ-Ditosylhydrazine is a tosylated derivative of hydrazine used as a reagent in organic chemistry reactions. 4-Methylbenzenesulfonic acid 2-[(4-methylphenyl)sulfonyl]hydrazide is a sulfonyl hydrazide compound also used as a reagent in organic synthesis. These chemicals are commonly utilized in the preparation of various organic compounds and are important intermediates in organic chemistry reactions.
Check Digit Verification of cas no
The CAS Registry Mumber 14062-05-6 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,4,0,6 and 2 respectively; the second part has 2 digits, 0 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 14062-05:
(7*1)+(6*4)+(5*0)+(4*6)+(3*2)+(2*0)+(1*5)=66
66 % 10 = 6
So 14062-05-6 is a valid CAS Registry Number.
InChI:InChI=1/C14H16N2O4S2/c1-11-3-7-13(8-4-11)21(17,18)15-16-22(19,20)14-9-5-12(2)6-10-14/h3-10,15-16H,1-2H3
14062-05-6Relevant articles and documents
A General Catalytic Route to Enantioenriched Isoindolinones and Phthalides: Application in the Synthesis of (S)-PD 172938
Ray, Sumit K.,Sadhu, Milon M.,Biswas, Rayhan G.,Unhale, Rajshekhar A.,Singh, Vinod K.
, (2019)
Chiral Br?nsted acid catalyzed enantioselective syntheses of isoindolinones and phthalides have been accomplished via tandem Mannich-lactamization and aldol-lactonization reactions, respectively. A variety of enantioenriched isoindolinones (up to 99% ee) and phthalides (up to 85% ee) containing α-diazoesters were afforded in excellent yields. Furthermore, a concise synthesis of (S)-PD 172938 has been demonstrated by using this protocol.
Hertz et al.
, p. 2508 (1977)
Jacobs
, p. 571,572 (1977)
ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS
-
Paragraph 0210-0211, (2021/02/05)
The present invention provides novel compounds which activate the Kv7 potassium channels. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders responsive to the activation of Kv7 potassium channels.